Replies to post #14988 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Do you think it would make sense to partner Europe and Asia/Japan and give up profits/rights, or float 10 million shares here and essentially raise the same type of money?

Honestly, I do not know which way it is going to go.

BTW, $150 million upfront for Europe is probably way on the high end, out of range, considering PCYC just got $150 million (and a lot more in royalties etc) for a WORLDWIDE partnership....for a drug which docs are saying will do for lymphoma what Gleevec did for CML.

Maybe they would get $150 million...I'd be thrilled.

Personally, I wish Roche or someone of that caliber, would take a minority stake in Ariad, the same way Roche did with Genentech (yes, i know, RHHBY spun off DNA as an IPO in 1999.... but u get what im saying)

[qutrader]

As to Harvey's statement on Europe, I'm fairly certain it was expressly set forth in a slide in today's presentation. I haven't had an opportunity to got to Ariad's website, so not sure if presentation has been posted.

[TwoNE1]

from todays press release:

ARIAD anticipates that this funding will also enable it to continue preparations for commercial launch of ponatinib in the United States and Europe and, if approved, to sell, market and distribute ponatinib in these and other markets on its own, allowing ARIAD to retain the substantial potential commercial value of ponatinib.